Autres langues MINAPHARM Pharmaceuticals

Actions

MIPH

EGS380G1C011

Produits pharmaceutiques

Cours en clôture Egyptian Exchange Autres places de cotation 29/07/2026			Varia. 5j.	Varia. 1 janv.
735,41 ^EGP	-1,03%		-1,51%	+110,60%

10/06	MINAPHARM Pharmaceuticals publie ses résultats annuels pour l'exercice clos au 31 décembre 2025	CI
05/05	Minapharm Pharmaceuticals : bénéfice net social annuel de 57,5 millions d'EGP	RE

Autres langues

10/06	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025
05/05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million
30/11	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million
30/11	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/09/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
14/09/25	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million
27/07/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025
27/07/25	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million
07/07/25	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals
12/06/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024
12/06/25	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million
26/05/25	Minapharm Pharmaceuticals FY Standalone Profit EGP 162.8 Million
26/03/25	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt
03/12/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
01/09/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
30/05/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2024
07/04/24	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries
04/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia
29/08/23	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
29/05/23	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2023
30/03/23	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2022
06/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa
06/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)
30/11/22	Bioventure, Minapharm Pharmaceuticals and Migentra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa